Samia Q. Khan, et al. EDIT-202, an AsCas12a and SLEEK™ gene-edited iPSC-derived NK cell therapy maintains prolonged persistence, high cytotoxicity, and enhanced in vivo control of solid tumors. Presented at The European Society of Gene and Cell Therapy (ESGCT) Annual Meeting, October 11-14, 2022.